What predicts failed cannulation and therapy at ERCP? Results of a large-scale multicenter analysis

医学 内镜逆行胰胆管造影术 置信区间 优势比 逻辑回归 外科 多中心研究 普通外科 内科学 随机对照试验 胰腺炎
作者
Elisabeth Williams,Reuben Ogollah,Peter Thomas,Richard F. Logan,Derrick Martin,Mark Wilkinson,M. Lombard
出处
期刊:Endoscopy [Georg Thieme Verlag KG]
卷期号:44 (07): 674-683 被引量:75
标识
DOI:10.1055/s-0032-1309345
摘要

Study background and aims: Predicting outcome at endoscopic retrograde cholangiopancreatography (ERCP) remains difficult. Our aim was to identify the risk factors for failed ERCP. Patients and methods: A prospective multicenter study of ERCP was performed in 66 hospitals across England. Data on 4561 patients were collected using a structured questionnaire completed at the time of ERCP. Results: In total 3209 patients had not had an ERCP prior to the study period. Considering their first ever ERCP, 2683 (84 %) were successfully cannulated, 2241(70 %) had all intended therapy completed, 360 (11 %) had some intended therapy completed, and 608 (19 %) were considered to have had a failed procedure. For first ever ERCP, factors associated with incomplete procedure (odds ratio and 95 % confidence interval) were: Billroth surgery (9.2, 3.2 – 26.7), precutting (2.0, 1.6 – 2.7), common bile duct (CBD) stone size and number (3.2, 2.1 – 4.8 for multiple, large stones), interventions in the pancreatic duct (3.4, 1.6 – 7.0), and CBD stenting (2.8, 2.2 – 3.5). Analysis of the 1352 patients who had undergone an ERCP prior to the study period indicated previous failed ERCP was also predictive of incomplete therapy (1.5, 1.1 – 2.1). The modified Schutz score correlated with ERCP completion, as did the Morriston score, even when modified to include only variables measurable before the procedure. Conclusion: This study confirms that patient- and procedure-based variables are key predictors of technical success and validates current methods of rating ERCP difficulty. Of note, a correlation between outcome and institutional factors, such as unit and endoscopist caseload, was not demonstrated.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
SweepingMonk应助虚心盼晴采纳,获得10
刚刚
1秒前
汉堡包应助XXF采纳,获得10
1秒前
wzh完成签到,获得积分10
1秒前
海底落日完成签到,获得积分20
1秒前
2秒前
科研通AI5应助123采纳,获得30
2秒前
烟花应助pi采纳,获得10
3秒前
汉堡包应助小木木壮采纳,获得10
3秒前
3秒前
yl发布了新的文献求助30
3秒前
菲菲呀发布了新的文献求助10
3秒前
3秒前
科研通AI5应助禾泽采纳,获得30
4秒前
坚强的樱发布了新的文献求助10
4秒前
英俊梦槐完成签到,获得积分10
4秒前
123发布了新的文献求助10
5秒前
5秒前
5秒前
白泽发布了新的文献求助10
6秒前
一条贤与发布了新的文献求助20
6秒前
6秒前
英俊谷秋完成签到,获得积分10
6秒前
6秒前
通~发布了新的文献求助10
7秒前
所所应助火星探险采纳,获得10
7秒前
7秒前
Guoyeye完成签到,获得积分10
7秒前
8秒前
阿芙乐尔完成签到 ,获得积分10
8秒前
_呱_发布了新的文献求助30
9秒前
9秒前
9秒前
Akim应助眼睛大的金鱼采纳,获得10
10秒前
10秒前
10秒前
11秒前
legend完成签到,获得积分10
11秒前
猪猪hero发布了新的文献求助10
11秒前
善学以致用应助Scidog采纳,获得10
11秒前
高分求助中
Continuum Thermodynamics and Material Modelling 3000
Production Logging: Theoretical and Interpretive Elements 2700
Social media impact on athlete mental health: #RealityCheck 1020
Ensartinib (Ensacove) for Non-Small Cell Lung Cancer 1000
Unseen Mendieta: The Unpublished Works of Ana Mendieta 1000
Bacterial collagenases and their clinical applications 800
El viaje de una vida: Memorias de María Lecea 800
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 基因 遗传学 物理化学 催化作用 量子力学 光电子学 冶金
热门帖子
关注 科研通微信公众号,转发送积分 3527849
求助须知:如何正确求助?哪些是违规求助? 3107938
关于积分的说明 9287239
捐赠科研通 2805706
什么是DOI,文献DOI怎么找? 1540033
邀请新用户注册赠送积分活动 716893
科研通“疑难数据库(出版商)”最低求助积分说明 709794